Cargando…
Review of Cisplatin and Oxaliplatin in Current Immunogenic and Monoclonal Antibody Treatments
Platinum-based chemotherapy agents initially transformed cancer treatment. However their effectiveness peaked as combined regimes showed little additional benefit in trials. New research frontiers developed with the discovery that conventional chemotherapy can induce immunological cell death by recr...
Autor principal: | Mehmood, Rao Khalid |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
PAGEPress Publications, Pavia, Italy
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4419649/ https://www.ncbi.nlm.nih.gov/pubmed/25992242 http://dx.doi.org/10.4081/oncol.2014.256 |
Ejemplares similares
-
Review of Cisplatin and Oxaliplatin in Current Immunogenic and Monoclonal Antibodies Perspective
por: Mehmood, Rao Khalid, et al.
Publicado: (2014) -
Immunogenicity of Innovative and Biosimilar Monoclonal Antibodies
por: Doevendans, Erik, et al.
Publicado: (2019) -
The effect of immunomodulators on the immunogenicity of TNF-blocking therapeutic monoclonal antibodies: a review
por: Krieckaert, Charlotte Louise Maria, et al.
Publicado: (2010) -
The Therapeutic Value of Monoclonal Antibodies Directed Against Immunogenic Tumor Glycoproteins
por: Arlen, Myron, et al.
Publicado: (2010) -
Long-term platinum retention after treatment with cisplatin and oxaliplatin
por: Brouwers, Elke EM, et al.
Publicado: (2008)